Literature DB >> 2872214

Soluble guanylate cyclase from rat lung exists as a heterodimer.

Y Kamisaki, S Saheki, M Nakane, J A Palmieri, T Kuno, B Y Chang, S A Waldman, F Murad.   

Abstract

The soluble form of guanylate cyclase (EC 4.6.1.2) from rat lung has been purified to homogeneity by a one-step immunoaffinity chromatographic procedure. The purified soluble guanylate cyclase has specific activities of 432 and 49.1 nmol of cyclic GMP formed per min/mg protein with manganese and magnesium ions as a cofactor, respectively. This represents a purification of approximately 2,000-fold with a 50% recovery. The native enzyme has a molecular weight of 150,000 and a Stokes radius of 4.8 nm as determined on Spherogel TSK-G3000SW gel permeation chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis results in two protein-staining bands with molecular weights of 82,000 and 70,000. The purified soluble guanylate cyclase was also subjected to native polyacrylamide gel electrophoresis, isoelectric focusing electrophoresis, ion exchange chromatography, and GTP-agarose affinity chromatography. These additional purification procedures confirmed the presence of a single protein peak coincident with enzyme activity. The two subunits separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis were shown to have different primary structures by immunoblotting with monoclonal and polyclonal antibodies prepared against purified soluble guanylate cyclase and by peptide mapping with papain or Staphylococcus aureus V8 protease treatment. These data demonstrate that soluble guanylate cyclase purified from rat lung is a heterodimer composed of 82,000- and 70,000-dalton subunits with different primary structures.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872214

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Soluble guanylate cyclases in the retina.

Authors:  Ari Sitaramayya
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

Review 2.  Receptor guanylyl cyclases.

Authors:  S K Wong; D L Garbers
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Dynamic ligand exchange in soluble guanylyl cyclase (sGC): implications for sGC regulation and desensitization.

Authors:  Ah-Lim Tsai; Vladimir Berka; Iraida Sharina; Emil Martin
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

4.  Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells.

Authors:  G Filippov; D B Bloch; K D Bloch
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.

Authors:  Y C Lee; E Martin; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  A mutation of the atrial natriuretic peptide (guanylyl cyclase-A) receptor results in a constitutively hyperactive enzyme.

Authors:  B J Wedel; D C Foster; D E Miller; D L Garbers
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 7.  Role of sGC-dependent NO signalling and myocardial infarction risk.

Authors:  Jana Wobst; Thorsten Kessler; Tan An Dang; Jeanette Erdmann; Heribert Schunkert
Journal:  J Mol Med (Berl)       Date:  2015-03-04       Impact factor: 4.599

Review 8.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 9.  CO-sensing mechanisms.

Authors:  Gary P Roberts; Hwan Youn; Robert L Kerby
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

10.  CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line.

Authors:  Iraida G Sharina; Emil Martin; Anthony Thomas; Karen L Uray; Ferid Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.